Trials that use: Logistic regression
New to this method? Read the tutorial →
5,900 results
- RESPIREIndependent statistical analysis of Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RESPIRE 1Independent statistical analysis of Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Response to Diaphragmatic Pacing in Subjects With Pompe Disease: Complete Statistical AnalysisIndependent statistical analysis of Response to Diaphragmatic Pacing in Subjects With Pompe Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02354651).
- Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema: Complete Statistical AnalysisIndependent statistical analysis of Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother: Complete Statistical AnalysisIndependent statistical analysis of Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01049828).
- RestorAATion-1Independent statistical analysis of A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1): primary endpoint results, effect estimate with confidence…
- RESTOREIndependent statistical analysis of A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- RestoreIndependent statistical analysis of RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02090114).
- ReSTOREIndependent statistical analysis of Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal: Complete Statistical AnalysisIndependent statistical analysis of Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03887429).
- REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE): Complete Statistical AnalysisIndependent statistical analysis of REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00271154).
- RETHINCIndependent statistical analysis of RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ReTHINKIndependent statistical analysis of Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.: primary endpoint results, effect estimate with confidence interval, sample-size…
- RETRIEVE-AMIIndependent statistical analysis of RETRIEVE-AMI Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05307965).
- Retrospective Encore Reverse Shoulder Prosthesis Study: Complete Statistical AnalysisIndependent statistical analysis of Retrospective Encore Reverse Shoulder Prosthesis Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00765037).
- RetroTIFIndependent statistical analysis of Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- REVEALIndependent statistical analysis of Evaluation of AMG 714 for Vitiligo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04338581).
- REVEALIndependent statistical analysis of REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01252953).
- REVEAL 1Independent statistical analysis of REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Reveal In-Office Implants: Complete Statistical AnalysisIndependent statistical analysis of Reveal In-Office Implants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01168427).
- Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04169529).
- REVEALPLAQUEIndependent statistical analysis of The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- REVELUTIONIndependent statistical analysis of RElugolix VErsus LeUprolide Cardiac Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05320406).
- Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib: Complete Statistical AnalysisIndependent statistical analysis of Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01466972).
- REVIRAL 1Independent statistical analysis of A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Revlimid in Transfusion Dependent Patients: Complete Statistical AnalysisIndependent statistical analysis of Revlimid in Transfusion Dependent Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01178814).
- Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01600053).
- RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows: Complete Statistical AnalysisIndependent statistical analysis of RHA® Redensity Eye Versus No-treatment for the Infra-Orbital Hollows: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04577898).
- RHINEIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Ri-CoDIFy 3Independent statistical analysis of Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04802837).
- RI-US XLIndependent statistical analysis of Resolute Integrity US Extended Length Sub-Study(RI US XL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01913600).
- RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy – A Randomized, Controlled Trial: Complete Statistical AnalysisIndependent statistical analysis of RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- RICHIndependent statistical analysis of Repair of Infected or Contaminated Hernias: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00617357).
- Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft: Complete Statistical AnalysisIndependent statistical analysis of Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- RIGHT: Rhythm ID Going Head-to-Head Trial: Complete Statistical AnalysisIndependent statistical analysis of RIGHT: Rhythm ID Going Head-to-Head Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00148954).
- Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder: Complete Statistical AnalysisIndependent statistical analysis of Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00523718).
- Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders: Complete Statistical AnalysisIndependent statistical analysis of Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RIPCOM1Independent statistical analysis of The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RISE AdultIndependent statistical analysis of RISE Adult Medication Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01779362).
- RISE-MIndependent statistical analysis of Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03634800).
- Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening: Complete Statistical AnalysisIndependent statistical analysis of Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Rituximab and ABVD for Hodgkin’s Patients: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and ABVD for Hodgkin's Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504504).
- Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue: Complete Statistical AnalysisIndependent statistical analysis of Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01611259).
- RN-Led Palliative and Supportive Care Intervention: Complete Statistical AnalysisIndependent statistical analysis of RN-Led Palliative and Supportive Care Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04570709).